On November 12, 2024, Brett Monia, CEO of Ionis Pharmaceuticals Inc (IONS, Financial), executed a sale of 6,630 shares of the company. According to the SEC Filing, the transaction occurred at a stock price of $38.05 per share. Following this transaction, the insider now owns 167,393 shares of Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc is a biotechnology firm focused on discovering and developing RNA-targeted therapeutics. The company has pioneered work in RNA-targeted drug discovery and development, providing treatments for diseases with significant unmet medical needs.
Over the past year, Brett Monia has sold a total of 160,676 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed within the company, where there have been 54 insider sells and no insider buys over the past year.
The stock of Ionis Pharmaceuticals Inc was trading at $38.05 on the day of the transaction, giving the company a market cap of approximately $5.88 billion. According to GF Value, the stock is currently Fairly Valued, with a price-to-GF-Value ratio of 1.03.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor for past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might be of interest to investors tracking insider behaviors and evaluating the stock's current valuation in relation to its intrinsic value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
